Key result
Treatment with oral prednisolone resulted in the normalization of serum VEGF levels and remission of RS3PE syndrome that developed during the clinical course of probable toxic shock syndrome.
Case Report (n=1)
No
This case report suggests that elevated blood VEGF due to toxic shock syndrome may induce RS3PE syndrome, highlighting the potential for concurrent occurrence of these conditions.
Answers are grounded in this paper and cite their sources.
May indicate steroid-responsive RS3PE in toxic shock syndrome; hypothesis-generating and needs prospective validation before clinical adoption.
BACKGROUND: Remitting seronegative symmetrical synovitis with pitting edema (RS3PE) is a rare syndrome characterized by "remitting," "seronegative" (namely rheumatoid factor-negative), and "symmetrical" synovitis with pitting edema on the dorsum of the hands and feet. Recently, there have been reports that serum vascular endothelial growth factor (VEGF) is elevated in this condition. CASE PRESENTATION: An 85-year-old man visited our department with a rash that had appeared 2 days earlier and a fever that had developed on the day of his visit. Based on clinical findings of fever, erythema exudativum multiforme, transitory hypotension, conjunctiva hyperemia, elevated creatine kinase, and desquamation, we suspected toxic shock syndrome (TSS). Therefore, we started treatment with vancomycin (1 g/day) and clindamycin (600 mg/day), after which his fever rapidly remitted. However, pitting edema on the dorsum of his hands and feet appeared on day 7, and the patient also had painful wrist and ankle joints. Additional tests were negative for rheumatoid factor, and anti-cyclic citrullinated protein antibodies were < 0.2 U/mL. Further, serum matrix metalloproteinase-3 (199.6 ng/mL; reference value ≤123.8 ng/mL) and serum VEGF (191 pg/mL; reference value ≤38.3 pg/mL) levels were elevated, and human leukocyte antigen-A2 was detected. The patient was thus diagnosed with RS3PE syndrome, for which he satisfied all four diagnostic criteria: 1) pitting edema in the limbs, 2) acute onset, 3) age ≥ 50 years, and 4) rheumatoid factor negativity. He was treated with oral prednisolone, resulting in the normalization of his serum VEGF level to 34.5 pg/mL 1 month after starting treatment. It is currently 1 year since disease onset, and although the patient has stopped taking prednisolone, there has been no recurrence of RS3PE syndrome. CONCLUSIONS: To the best of our knowledge, this is the first reported case of a patient developing RS3PE syndrome during the clinical course of TSS. We propose that the onset mechanism involved an increase in blood VEGF due to TSS, which induced RS3PE syndrome. As serum VEGF becomes elevated with both severe infections associated with shock and RS3PE syndrome, awareness that these conditions can occur concurrently is essential.
No takes yet. Share an insight, caveat, or question.
Kyotani et al. (2018) conducted a case report in RS3PE syndrome and probable toxic shock syndrome (n=1). Prednisolone was evaluated on Normalization of serum VEGF and remission of RS3PE syndrome. Treatment with oral prednisolone resulted in the normalization of serum VEGF levels and remission of RS3PE syndrome that developed during the clinical course of probable toxic shock syndrome.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: